Sagimet Biosciences’ Post

👨🔬Meet Dr. Ben J. Gu, Principal Science and Head of the Innate Phagocytosis Lab at the Florey Institute, University of Melbourne. Established in 2012, his lab focuses on pioneering novel diagnostic tools and therapeutic drugs for Alzheimer’s disease. We're honored to support their groundbreaking research with our INFORS HT bioreactors. "Our lab has been using INFORS HT bioreactors for nearly 10 years, from Minifors to Labfors. With their state-of-the-art design, we can easily optimize culture conditions for various applications. The stability and reliability of each batch are unmatched, allowing us to prepare our work as scheduled." - Dr. Ben Gu, Innate Phagocytosis Lab. 🔗Want to learn more about our bench-top bioreactors? https://ow.ly/F4RK50SnbTu #InforsHT #Bioreactors #ScientificInnovation #LabEfficiency #ResearchSupport #AlzheimersResearch #CustomerSatisfaction #ScientificBreakthroughs

An independent study published in Nature has unequivocally demonstrated that Sierra Molecular's AssayAssure outperforms other assays in accurately characterizing the urine microbiome. Titled "Enhancing the Robustness and Resilience of Molecular Diagnostic Assays for In Vitro Diagnostics," this study highlights the critical importance of assay robustness in molecular diagnostics. Researchers found that AssayAssure consistently delivers more precise and reliable results, providing invaluable insights into urinary tract health. At Sierra Molecular, we take pride in our commitment to excellence and innovation. AssayAssure's unmatched performance in urine microbiome analysis reaffirms our dedication to advancing diagnostic accuracy and improving patient care. Discover how AssayAssure can elevate your diagnostic capabilities. Learn more about the study in Nature Communications: https://lnkd.in/etQaPzfb #SierraMolecular #AssayAssure #MolecularDiagnostics #UrineMicrobiome #HealthcareInnovation #samplepreservation #diagnosticcapabilities #ambienttemperature #lab #ambienttemperaturepreservation

The August issue of the Journal of Pharmacokinetics and Pharmacodynamics has been issued. There are a number of interesting articles within: * ISoP provides an update on their PMx Mentorship Program. * Ting Chen and colleagues from Don Mager's group at Buffalo present a sequential and joint model of tumor dynamics and survival for durvalumab. * Sara Soufsaf and colleagues from Montreal present a PKPD model on DA and NE transporter occupancy. * Christos Kaikousidis and Aristides Dokoumetzidis present how to implement nonlinear mixed effect models using fractional differential equations. * Carolina Llanos-Paez and colleagues from Uppsala University present a joint model of FEV(1) and exacerbation rate in COPD patients, and * Lisa Amann and Sebastian Wicha compare the frem (full random effects model) to stepwise covariate modeling. Journal of Pharmacokinetics and Pharmacodynamics | Volume 50, issue 4 (springer.com) https://lnkd.in/gXqQH4Uc

The American Society of Hematology (ASH) 2023 Friday Satellite Symposium brought together an international faculty of experts who presented, debated, and discussed recent advances in the diagnosis, classification, and management of Myelodysplastic Syndromes (MDS). This summary highlights key presentations, showcasing recent data, new tools, current practice evidence, and future directions for optimizing MDS care. Learn more: https://bit.ly/3RZGCUQ Don’t miss out on the 2024 Friday Satellite Symposia (FSS) held on Friday, December 6, 2024, preceding the 66th ASH Annual Meeting & Exposition. This year’s theme is “Let’s Overcome the Challenges”. #TreatmentOptions #ClinicalTrials #ClinicalResearch #Innovation #MedicalAdvancement

Something new is coming to PVRI...Introducing our webinar series, PVRI 2023/24 Digital, launching November 2023. The series follows the success of our 2021/22 series and has been developed by Dr Patricia Thistlethwaite, MD, PhD, University of California San Diego. Upcoming webinars: 🌐 PAH risk calculators – state of the art assessment 🌐 Controversies in CTEPH: pro-con debate 🌐 Clinical trials for PAH: what are we learning? 🌐 Enhancing drug development for paediatric PH: an integrative perspective 🌐 Ion channels: pathogenic role & therapeutic intervention in PAH 🌐 Single cell transcriptional profiling in lung health and PAH Learn more about the scientific programme, book onto upcoming webinars or watch recordings of missed webinars here: https://pvri.link/digital #PulmonaryHypertension

Prof. Dr. Hilmar Bading at Heidelberg University has led a breakthrough in ALS research with FP802, a novel 'TwinF interface inhibitor' that targets damaging protein interactions involved in ALS. Demonstrating efficacy in ALS models by preserving motor neurons and enhancing motor functions, FP802 offers new hope for treatment. Developed in collaboration with FundaMental Pharma and supported by leading institutions, this research highlights a significant step towards clinical trials. Dr. Jing Yan's involvement underscores the project's collaborative effort to combat this challenging disease, promising a brighter future for ALS patients. #InnovativeTreatment #NeurodegenerativeDiseases #ALSResearch #FutureOfHealthcare #Healthcare 🔗 For more details, explore the full article: https://lnkd.in/ghBhrVRh

Precision medicine innovation and the role of ecosystems This whitepaper, Fuelling the future: Precision medicine innovation and the role of ecosystems, examines how the future of drug discovery and precision medicine can be enhanced by life science ecosystems such as those created by the UK's leading property developer to the science and technology sectors, Bruntwood SciTech. In the whitepaper, you will discover: - The evolution of precision diagnostics for oncology in the North West of England - How life science ecosystems enable key breakthroughs in precision medicine - A view into the future of precision medicine developments. Download Whitepaper https://lnkd.in/eKYQ5d-M Brought to you by Bruntwood SciTech #PrecisionMedicine #DrugDiscovery #Diagnostics

APIS has been featured in the Bruntwood SciTech and Drug Discovery World whitepaper: 'Fuelling the future: Precision medicine innovation and the role of ecosystems' Check it out below!

Join us Thursday, September 14th, for a webinar presented by Dr. Rajesh Khanna, Director of the New York University Pain Research Center and an internationally known expert in #painresearch. Dr. Khanna will delve into the clinical evidence supporting the importance of NaV1.7, its potential in #pharmacogenomics, the reasons behind previous failures in translating this target and the potential of allosteric modulation of NaV1.7 as a pathway for future therapeutic advancements. #drugdiscovery #earlyhumaninsights

Another must see pain webinar by AnaBios Corporation - looking forward to this Rajesh Khanna !!